Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (131-140 of 268) with videos related to

Pageof 27
Sort By:
Journal of the National Cancer Institute|December 14, 2025
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancerAlison M Schram, Soo-Ryum Yang, Genessa Kahn, et al.
JAMA Oncology|January 9, 2025
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology TherapiesKanika Arora, Sarah P Suehnholz, Hongxin Zhang, et al.
JAMA Ophthalmology|September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated RetinopathyJasmine H Francis, James J Harding, Alison M Schram, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
JCO Precision Oncology|October 6, 2022
Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With <i>ALK</i>/<i>ROS1</i>/<i>RET</i>-Rearranged Lung CancersHarper Hubbeling, Noura Choudhury, Jessica Flynn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
Pageof 27

Showing results (131-140 of 268) with videos related to

Sort By:
Pageof 27
Journal of the National Cancer Institute|December 14, 2025
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancerAlison M Schram, Soo-Ryum Yang, Genessa Kahn, et al.
JAMA Oncology|January 9, 2025
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology TherapiesKanika Arora, Sarah P Suehnholz, Hongxin Zhang, et al.
JAMA Ophthalmology|September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated RetinopathyJasmine H Francis, James J Harding, Alison M Schram, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
JCO Precision Oncology|October 6, 2022
Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With <i>ALK</i>/<i>ROS1</i>/<i>RET</i>-Rearranged Lung CancersHarper Hubbeling, Noura Choudhury, Jessica Flynn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
Pageof 27